Scott Loughhead, PhD

Joined SQZ Biotech in 2015 and has been instrumental in the translational research for both SQZ® APC and SQZ® eAPC programs from preclinical proof-of-concept to successful IND submission and approval. Dr. Loughhead has worked closely with Roche since the inception of our collaboration. Over 15 years of immunology experience. Holds PhD in Immunology from Harvard University where he focused on immune surveillance by CD8 T cells.